Stereotactic Laser Ablation as Treatment of Brain Metastases Recurring after Stereotactic Radiosurgery

A Systematic Literature Review

Ali A. Alattar, Jiri Bartek, Veronica L. Chiang, Alireza M. Mohammadi, Gene H. Barnett, Andrew Sloan, Clark C Chen

Research output: Contribution to journalReview article

Abstract

Background: The optimal treatment of brain metastases recurring after radiosurgery (BMRS) remains an area of active investigation. Stereotactic laser ablation (SLA, also known as laser interstitial thermal therapy) has recently emerged as a potential treatment option. Objective: To summarize the available literature on SLA as treatment of BMRS and synthesize findings on local control, overall survival, neurologic outcome, imaging findings, morbidity, and postprocedure clinical course. Methods: We performed a comprehensive search of PubMed for articles investigating SLA as treatment of BMRS. Results: Thirteen peer-reviewed publications met our search criteria. Local control was a function of the percentage of tumor that was thermally ablated. In completely ablated tumors, 3-month local control was 80%–100%. Median survival ranged from 5.8 to 19.8 months. About two-thirds of treated lesions showed postablation expansion of contrast-enhancing volume and fluid-attenuated inversion recovery volume. Expansion could start within an hour of treatment, and resolution typically occurred within 6 months. Notably, maximal expanded contrast-enhancing volume could reach >3-fold the preoperative lesion volume. The incidence of SLA-related permanent neurologic injuries was <10%. The most common complications were hemorrhage, thermal injury causing neurologic deficit, and malignant cerebral edema. Nearly all patients were treated with dexamethasone, but there was variability in the dose and duration of therapy. Median hospital stay was 1–2 days (range, 1–5 days), and most treated patients were discharged home (range, 59.5%–100%). Conclusion: Our analysis provides support for continued development of SLA as a treatment of BMRS. Standardization of periprocedural management will be needed.

Original languageEnglish (US)
Pages (from-to)134-142
Number of pages9
JournalWorld neurosurgery
Volume128
DOIs
StatePublished - Aug 1 2019

Fingerprint

Radiosurgery
Laser Therapy
Neoplasm Metastasis
Brain
Therapeutics
Hot Temperature
Homing Behavior
Nervous System Trauma
Survival
Brain Edema
Neurologic Manifestations
PubMed
Dexamethasone
Nervous System
Publications
Length of Stay
Neoplasms
Lasers
Hemorrhage
Morbidity

Keywords

  • Brain metastases recurring after stereotactic radiosurgery
  • LITT
  • Laser interstitial thermal therapy
  • SLA
  • Stereotactic laser ablation

Cite this

Stereotactic Laser Ablation as Treatment of Brain Metastases Recurring after Stereotactic Radiosurgery : A Systematic Literature Review. / Alattar, Ali A.; Bartek, Jiri; Chiang, Veronica L.; Mohammadi, Alireza M.; Barnett, Gene H.; Sloan, Andrew; Chen, Clark C.

In: World neurosurgery, Vol. 128, 01.08.2019, p. 134-142.

Research output: Contribution to journalReview article

Alattar, Ali A. ; Bartek, Jiri ; Chiang, Veronica L. ; Mohammadi, Alireza M. ; Barnett, Gene H. ; Sloan, Andrew ; Chen, Clark C. / Stereotactic Laser Ablation as Treatment of Brain Metastases Recurring after Stereotactic Radiosurgery : A Systematic Literature Review. In: World neurosurgery. 2019 ; Vol. 128. pp. 134-142.
@article{2c3f58a7a94e461993d0544064ac2c8b,
title = "Stereotactic Laser Ablation as Treatment of Brain Metastases Recurring after Stereotactic Radiosurgery: A Systematic Literature Review",
abstract = "Background: The optimal treatment of brain metastases recurring after radiosurgery (BMRS) remains an area of active investigation. Stereotactic laser ablation (SLA, also known as laser interstitial thermal therapy) has recently emerged as a potential treatment option. Objective: To summarize the available literature on SLA as treatment of BMRS and synthesize findings on local control, overall survival, neurologic outcome, imaging findings, morbidity, and postprocedure clinical course. Methods: We performed a comprehensive search of PubMed for articles investigating SLA as treatment of BMRS. Results: Thirteen peer-reviewed publications met our search criteria. Local control was a function of the percentage of tumor that was thermally ablated. In completely ablated tumors, 3-month local control was 80{\%}–100{\%}. Median survival ranged from 5.8 to 19.8 months. About two-thirds of treated lesions showed postablation expansion of contrast-enhancing volume and fluid-attenuated inversion recovery volume. Expansion could start within an hour of treatment, and resolution typically occurred within 6 months. Notably, maximal expanded contrast-enhancing volume could reach >3-fold the preoperative lesion volume. The incidence of SLA-related permanent neurologic injuries was <10{\%}. The most common complications were hemorrhage, thermal injury causing neurologic deficit, and malignant cerebral edema. Nearly all patients were treated with dexamethasone, but there was variability in the dose and duration of therapy. Median hospital stay was 1–2 days (range, 1–5 days), and most treated patients were discharged home (range, 59.5{\%}–100{\%}). Conclusion: Our analysis provides support for continued development of SLA as a treatment of BMRS. Standardization of periprocedural management will be needed.",
keywords = "Brain metastases recurring after stereotactic radiosurgery, LITT, Laser interstitial thermal therapy, SLA, Stereotactic laser ablation",
author = "Alattar, {Ali A.} and Jiri Bartek and Chiang, {Veronica L.} and Mohammadi, {Alireza M.} and Barnett, {Gene H.} and Andrew Sloan and Chen, {Clark C}",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.wneu.2019.04.200",
language = "English (US)",
volume = "128",
pages = "134--142",
journal = "World Neurosurgery",
issn = "1878-8750",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Stereotactic Laser Ablation as Treatment of Brain Metastases Recurring after Stereotactic Radiosurgery

T2 - A Systematic Literature Review

AU - Alattar, Ali A.

AU - Bartek, Jiri

AU - Chiang, Veronica L.

AU - Mohammadi, Alireza M.

AU - Barnett, Gene H.

AU - Sloan, Andrew

AU - Chen, Clark C

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Background: The optimal treatment of brain metastases recurring after radiosurgery (BMRS) remains an area of active investigation. Stereotactic laser ablation (SLA, also known as laser interstitial thermal therapy) has recently emerged as a potential treatment option. Objective: To summarize the available literature on SLA as treatment of BMRS and synthesize findings on local control, overall survival, neurologic outcome, imaging findings, morbidity, and postprocedure clinical course. Methods: We performed a comprehensive search of PubMed for articles investigating SLA as treatment of BMRS. Results: Thirteen peer-reviewed publications met our search criteria. Local control was a function of the percentage of tumor that was thermally ablated. In completely ablated tumors, 3-month local control was 80%–100%. Median survival ranged from 5.8 to 19.8 months. About two-thirds of treated lesions showed postablation expansion of contrast-enhancing volume and fluid-attenuated inversion recovery volume. Expansion could start within an hour of treatment, and resolution typically occurred within 6 months. Notably, maximal expanded contrast-enhancing volume could reach >3-fold the preoperative lesion volume. The incidence of SLA-related permanent neurologic injuries was <10%. The most common complications were hemorrhage, thermal injury causing neurologic deficit, and malignant cerebral edema. Nearly all patients were treated with dexamethasone, but there was variability in the dose and duration of therapy. Median hospital stay was 1–2 days (range, 1–5 days), and most treated patients were discharged home (range, 59.5%–100%). Conclusion: Our analysis provides support for continued development of SLA as a treatment of BMRS. Standardization of periprocedural management will be needed.

AB - Background: The optimal treatment of brain metastases recurring after radiosurgery (BMRS) remains an area of active investigation. Stereotactic laser ablation (SLA, also known as laser interstitial thermal therapy) has recently emerged as a potential treatment option. Objective: To summarize the available literature on SLA as treatment of BMRS and synthesize findings on local control, overall survival, neurologic outcome, imaging findings, morbidity, and postprocedure clinical course. Methods: We performed a comprehensive search of PubMed for articles investigating SLA as treatment of BMRS. Results: Thirteen peer-reviewed publications met our search criteria. Local control was a function of the percentage of tumor that was thermally ablated. In completely ablated tumors, 3-month local control was 80%–100%. Median survival ranged from 5.8 to 19.8 months. About two-thirds of treated lesions showed postablation expansion of contrast-enhancing volume and fluid-attenuated inversion recovery volume. Expansion could start within an hour of treatment, and resolution typically occurred within 6 months. Notably, maximal expanded contrast-enhancing volume could reach >3-fold the preoperative lesion volume. The incidence of SLA-related permanent neurologic injuries was <10%. The most common complications were hemorrhage, thermal injury causing neurologic deficit, and malignant cerebral edema. Nearly all patients were treated with dexamethasone, but there was variability in the dose and duration of therapy. Median hospital stay was 1–2 days (range, 1–5 days), and most treated patients were discharged home (range, 59.5%–100%). Conclusion: Our analysis provides support for continued development of SLA as a treatment of BMRS. Standardization of periprocedural management will be needed.

KW - Brain metastases recurring after stereotactic radiosurgery

KW - LITT

KW - Laser interstitial thermal therapy

KW - SLA

KW - Stereotactic laser ablation

UR - http://www.scopus.com/inward/record.url?scp=85066336575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066336575&partnerID=8YFLogxK

U2 - 10.1016/j.wneu.2019.04.200

DO - 10.1016/j.wneu.2019.04.200

M3 - Review article

VL - 128

SP - 134

EP - 142

JO - World Neurosurgery

JF - World Neurosurgery

SN - 1878-8750

ER -